123 related articles for article (PubMed ID: 8311654)
1. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas.
Zhang SY; Ruggeri B; Agarwal P; Sorling AF; Obara T; Ura H; Namiki M; Klein-Szanto AJ
Arch Pathol Lab Med; 1994 Feb; 118(2):150-4. PubMed ID: 8311654
[TBL] [Abstract][Full Text] [Related]
2. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.
Kawahira H; Kobayashi S; Kaneko K; Asano T; Ochiai T
Hepatogastroenterology; 2000; 47(34):973-7. PubMed ID: 11020860
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
[TBL] [Abstract][Full Text] [Related]
4. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival.
Sessa F; Bonato M; Bisoni D; Ranzani GN; Capella C
Eur J Histochem; 1998; 42 Spec No():67-76. PubMed ID: 10076772
[TBL] [Abstract][Full Text] [Related]
5. p53 protein expression as prognostic factor in human pancreatic cancer.
Sato Y; Nio Y; Song MM; Sumi S; Hirahara N; Minari Y; Tamura K
Anticancer Res; 1997; 17(4A):2779-88. PubMed ID: 9252715
[TBL] [Abstract][Full Text] [Related]
6. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
Ruggeri B; Zhang SY; Caamano J; DiRado M; Flynn SD; Klein-Szanto AJ
Oncogene; 1992 Aug; 7(8):1503-11. PubMed ID: 1630814
[TBL] [Abstract][Full Text] [Related]
7. [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
Tomaszewska R
Folia Med Cracov; 1999; 40(1-2):101-41. PubMed ID: 10909469
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
[TBL] [Abstract][Full Text] [Related]
9. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
[TBL] [Abstract][Full Text] [Related]
10. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
Nishikawa N; Kimura Y; Okita K; Zembutsu H; Furuhata T; Katsuramaki T; Kimura S; Asanuma H; Hirata K
J Hepatobiliary Pancreat Surg; 2006; 13(4):327-35. PubMed ID: 16858545
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of molecular biological factors in intraductal papillary-mucinous tumors and mucinous cystic tumors of the pancreas.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Tanaka M; Manabe T
Scand J Gastroenterol; 2004 Nov; 39(11):1159-65. PubMed ID: 15545177
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
13. Infrequent expression of p21 is related to altered p53 protein in pancreatic carcinoma.
Hu YX; Watanabe H; Ohtsubo K; Yamaguchi Y; Ha A; Motoo Y; Okai T; Sawabu N
Clin Cancer Res; 1998 May; 4(5):1147-52. PubMed ID: 9607571
[TBL] [Abstract][Full Text] [Related]
14. [Expressions of p53 and Gadd45a proteins in human pancreatic cancer and their clinicopathological significance].
Dong M; Zhou JP; Kong FM; Guo KJ; Tian YL; Dong YT
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):628-32. PubMed ID: 16274047
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
Castiglioni T; Elsner B; Curutchet HP; Montesinos M; Debonis D
Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771
[TBL] [Abstract][Full Text] [Related]
16. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.
Huang L; Lang D; Geradts J; Obara T; Klein-Szanto AJ; Lynch HT; Ruggeri BA
Mol Carcinog; 1996 Feb; 15(2):85-95. PubMed ID: 8599583
[TBL] [Abstract][Full Text] [Related]
17. P53 protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis.
Aizawa S; Sasaki M; Wada R; Koyama M; Yagihashi S
J Surg Oncol; 1996 Aug; 62(4):279-83. PubMed ID: 8691842
[TBL] [Abstract][Full Text] [Related]
18. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
19. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
20. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
